Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Arrowhead Pharmaceuticals (ARWR) Depreciation & Amortization (IS) (2016 - 2017)

Historic Depreciation & Amortization (IS) for Arrowhead Pharmaceuticals (ARWR) over the last 7 years, with Q4 2017 value amounting to $1.1 million.

  • Arrowhead Pharmaceuticals' Depreciation & Amortization (IS) fell 374.81% to $1.1 million in Q4 2017 from the same period last year, while for Dec 2017 it was $4.6 million, marking a year-over-year increase of 2724.22%. This contributed to the annual value of $4.7 million for FY2017, which is 4387.65% up from last year.
  • As of Q4 2017, Arrowhead Pharmaceuticals' Depreciation & Amortization (IS) stood at $1.1 million, which was down 374.81% from $1.2 million recorded in Q3 2017.
  • Arrowhead Pharmaceuticals' Depreciation & Amortization (IS)'s 5-year high stood at $9.2 million during Q3 2013, with a 5-year trough of $276054.0 in Q2 2014.
  • For the 5-year period, Arrowhead Pharmaceuticals' Depreciation & Amortization (IS) averaged around $1.2 million, with its median value being $803912.0 (2016).
  • In the last 5 years, Arrowhead Pharmaceuticals' Depreciation & Amortization (IS) tumbled by 3920.67% in 2014 and then surged by 17387.66% in 2015.
  • Arrowhead Pharmaceuticals' Depreciation & Amortization (IS) (Quarter) stood at $403405.0 in 2013, then dropped by 28.1% to $290039.0 in 2014, then surged by 173.88% to $794349.0 in 2015, then surged by 49.26% to $1.2 million in 2016, then fell by 3.75% to $1.1 million in 2017.
  • Its Depreciation & Amortization (IS) stands at $1.1 million for Q4 2017, versus $1.2 million for Q3 2017 and $1.2 million for Q2 2017.